Catalyst Pharmaceuticals (NASDAQ:CPRX) Given Coverage Optimism Score of 0.15

News coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1030885474393 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $3.92 on Monday. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The stock has a market capitalization of $401.70, a price-to-earnings ratio of -18.67 and a beta of 1.68.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. equities research analysts anticipate that Catalyst Pharmaceuticals will post -0.22 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on CPRX shares. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 1st. SunTrust Banks set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 31st. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Finally, Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $6.25.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-cprx-getting-somewhat-positive-press-coverage-report-shows/1814067.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.